<DOC>
	<DOCNO>NCT00005643</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness liposomal doxorubicin treat patient advanced recurrent sarcoma uterus .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Sarcoma Uterus</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate antitumor activity doxorubicin HCl liposome patient recurrent advance uterine sarcoma . II . Determine nature degree toxicity drug patient population . OUTLINE : Patients receive doxorubicin HCl liposome IV 1 hour . Treatment continue every 4 week absence unacceptable toxicity disease progression . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 20-30 patient accrue study within 1-1.5 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced , persistent recurrent uterine sarcoma document disease progression appropriate local therapy Leiomyosarcoma Malignant mixed mullerian tumor ( mixed mesodermal tumor , mixed heterologous mesenchymal sarcoma ) Mixed malignant Muellerian tumor ( carcinosarcoma , homologous mesenchymal sarcoma ) Endometrial stromal sarcoma Other uterine sarcoma Considered incurable Bidimensionally measurable disease consist abdominal , pelvic , chest , mass palpation , xray , compute tomography , ultrasound PATIENT CHARACTERISTICS : Age : Over 21 Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 3 time ULN Alkaline phosphatase great 3 time ULN Renal : Creatinine great 1.5 mg/dL Cardiovascular : LVEF normal MUGA scan Other : No clinically significant infection No malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior therapy cytotoxic drug No prior doxorubicin HCl liposome No prior doxorubicin great 360 mg/m2 No concurrent antineoplastic agent Endocrine therapy : Not specify Radiotherapy : Recovered prior radiotherapy No prior radiotherapy malignancy Surgery : Recovered prior surgery Other : No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine carcinosarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>endometrial stromal sarcoma</keyword>
</DOC>